Overview

Trial of Dasatinib in Advanced Sarcomas

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborator:
Bristol-Myers Squibb
Treatments:
Dasatinib